株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バイオシミラーの世界市場 - 産業洞察、動向、見通し、市場機会の分析 2017年~2025年

Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025

発行 Coherent Market Insights 商品コード 833116
出版日 ページ情報 英文 231 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
バイオシミラーの世界市場 - 産業洞察、動向、見通し、市場機会の分析 2017年~2025年 Biosimilars Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2017-2025
出版日: 2019年04月16日 ページ情報: 英文 231 Pages
概要

バイオシミラーは有効成分を含有するバイオ医薬品です。先発医薬品の特許が満了する場合に製造され、先発医薬品と同等性が認められます。癌や腫瘍、そして喘息や関節炎などといった非感染性疾患の治療に用いられています。

当レポートでは、世界のバイオシミラー市場を調査し、市場の概要、医薬品クラス・治療領域・流通経路・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、パイプライン分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概要

  • レポート概要
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:医薬品クラス別
    • 市場スニペット:治療領域別
    • 市場スニペット:流通経路別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 影響分析
  • 市場動向
  • 主な開発
  • パイプライン分析
  • サプライチェーン分析
  • バイオシミラーの費用対効果
  • 償還シナリオ
  • 規制状況
  • 疫学分析
  • PEST分析
  • ファイブフォース分析

第4章 世界のバイオシミラー市場:医薬品クラス別

  • イントロダクション
  • 組み換えヒト成長ホルモン(rhGH)
  • 顆粒球コロニー刺激因子(フィルグラスチム)
  • インスリン
  • 抗凝固薬
  • 融合タンパク質
  • エリスロポエチン(EPO)
  • モノクローナル抗体
  • フォリトロピン
  • その他

第5章 世界のバイオシミラー市場:治療領域別

  • イントロダクション
  • 癌・腫瘍
  • 免疫
  • 血液
  • ホルモン療法
  • 代謝異常
  • その他

第6章 世界のバイオシミラー市場:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • 専門薬局

第7章 世界のバイオシミラー市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中南米
  • アフリカ
  • 中東

第8章 競争環境

  • 企業プロファイル
    • Novartis AG
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Amgen, Inc.
    • Dr. Reddy's Laboratories
    • Sanofi S.A.
  • アナリストの意見

第9章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Biosimilars are biopharmaceutical drugs that have active components and are similar to the drugs, which have been previously licensed. They are identical copies of the original product and can be manufactured only when the patent for the original innovator product expires. Biosimilars are majorly used in therapeutic applications for the treatment of various types of cancer and non-communicable diseases (asthma and arthritis).

Increasing prevalence of cancer is expected to boost growth of the biosimilars market. For instance, according to National Institute of Cancer Prevention and Research (NICPR), in 2018, 1,62,468 new cases and 87,090 deaths were reported due to breast cancer in India. Biosimilars are designed to be highly similar to originator biologic products, which represents an opportunity to increase access and reduce costs for patients and healthcare systems.

Market Dynamics

Increasing number of biosimilar approvals in clinical management of various diseases such as diabetes and hormonal imbalance is expected to drive growth of the biosimilars market. According to the Generics and Biosimilars Initiative (GABI) 2017 report, around 40 different biosimilars were approved in Europe, covering several different therapeutic classes: granulocyte colony-stimulating factors, and erythropoiesis-stimulating agents (ESAs), among others.

Moreover, increasing research and development in biosimilars, robust biosimilar pipeline portfolio, and support from healthcare regulatory bodies in fast lining biosimilar approvals are some of the major factors that are expected to drive growth of the market. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) both provide guidance for the development of biosimilar drugs. However, stringent regulatory guidelines for development and manufacturing of biosimilars and fragile process of biosimilars production are expected to negatively impact growth of the global biosimilars market.

Key features of the study:

  • This report provides in-depth analysis of the biosimilars market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global biosimilars market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy's Laboratories, and Sanofi S.A.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global biosimilars market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for biosimilars market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Biosimilars Market, By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
  • Global Biosimilars Market, By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
  • Global Biosimilars Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Global Biosimilars Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Class:
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-Stimulating Factor
    • Insulin
    • Anticoagulants
    • Fusion Proteins
    • Erythropoietin
    • Monoclonal Antibodies
    • Follitropin
    • Others
      • By Therapy Type:
    • Oncology
    • Immunology
    • Hematology
    • Hormone Therapy
    • Metabolic Disorders
    • Others
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Specialty Pharmacies
  • Company Profiles
    • Novartis AG *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Celltrion Healthcare Co., Ltd.
    • Biocon Limited
    • Amgen, Inc.
    • Dr. Reddy's Laboratories
    • Sanofi S.A.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Therapy Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Pipeline Analysis
  • Supply Chain Analysis
  • Cost Effectiveness of Biosimilars
  • Reimbursement Scenario
  • Regulatory Landscape
  • Epidemiology Analysis
  • PEST Analysis
  • Porter's Five Forces model

4. Global Biosimilars Market, By Drug Class, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Recombinant Human Growth Hormone (rhGH)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Granulocyte Colony-Stimulating Factor (Filgrastim)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Insulin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Anticoagulants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Fusion Proteins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Erythropoietin (EPO)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Monoclonal Antibodies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Follitropin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

5. Global Biosimilars Market, By Therapy Type, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Hematology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Hormone Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Metabolic Disorders
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

6. Global Biosimilars Market, By Distribution Channel, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017 - 2026
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)
  • Specialty Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2026, (US$ Million)

7. Global Biosimilars Market, By Region, 2018 - 2026, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2026
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Therapy Type, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2018 - 2026, (US$ Million)
    • Market Size and Forecast, By Country, 2018 - 2026, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Company Profiles
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Celltrion Healthcare Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biocon Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amgen, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Dr. Reddy's Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Sanofi S.A.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top